FDA panel recommends approval of Teva's biotech asthma drug
December 10, 2015 at 08:54 AM EST
TEL AVIV, Dec 10 (Reuters) - Israel-based Teva Pharmaceutical Industries said on Thursday the U.S. Food and Drug Administration's pulmonary-allergy drugs advisory committee had recommended approval of reslizumab in patients aged 18 and over.
